OneClinical Provides a Full Spectrum of Software Products and Services for the Regulated Life Sciences Industry.
Princeton, NJ-June 12, 2006-Today TAKE Solutions, Inc. announced the formation of the OneClinical™ brand of life sciences offerings as part of its merger with Applied Clinical Intelligence (Philadelphia, PA) and OnSphere Corporation (Raleigh, NC). OneClinical combines a full spectrum of proven data and document management software products and services for clinical trials, drug and device development lifecycles.
"The merger of TAKE Solutions, ACI, and OnSphere enhances our ability to help our clients improve efficiencies in drug and medical device development and product safety. We can now offer our clients global scalability as well as a robust suite of regulatory-compliant process efficiency software" said Dr. Jonathan Seltzer, President, ACI & Chief Medical Officer, TAKE Solutions Global Life Sciences.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Reblozyl Misses Primary Endpoint in Phase III Myelofibrosis Trial but Shows Clinical Promise
July 21st 2025The Phase III INDEPENDENCE trial (NCT04717414) failed to meet its primary endpoint of achieving transfusion independence in patients with myelofibrosis-associated anemia treated with Reblozyl (luspatercept-aamt).
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.